WO2000023091A3 - Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases - Google Patents

Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases Download PDF

Info

Publication number
WO2000023091A3
WO2000023091A3 PCT/DK1999/000567 DK9900567W WO0023091A3 WO 2000023091 A3 WO2000023091 A3 WO 2000023091A3 DK 9900567 W DK9900567 W DK 9900567W WO 0023091 A3 WO0023091 A3 WO 0023091A3
Authority
WO
WIPO (PCT)
Prior art keywords
kappa
kinases
redistribution
targeting
interference
Prior art date
Application number
PCT/DK1999/000567
Other languages
French (fr)
Other versions
WO2000023091A2 (en
Inventor
Per O G Arkhammar
Bernard Robert Terry
Kurt Marshall Scudder
Sara Petersen Bjoern
Ole Thastrup
Original Assignee
Bioimage A S
Per O G Arkhammar
Bernard Robert Terry
Kurt Marshall Scudder
Sara Petersen Bjoern
Ole Thastrup
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioimage A S, Per O G Arkhammar, Bernard Robert Terry, Kurt Marshall Scudder, Sara Petersen Bjoern, Ole Thastrup filed Critical Bioimage A S
Priority to EP99948735A priority Critical patent/EP1146888A2/en
Priority to JP2000576864A priority patent/JP2003526608A/en
Priority to CA002346937A priority patent/CA2346937A1/en
Priority to AU61899/99A priority patent/AU6189999A/en
Publication of WO2000023091A2 publication Critical patent/WO2000023091A2/en
Publication of WO2000023091A3 publication Critical patent/WO2000023091A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)

Abstract

The application describes a novel mechanism of action, that is modulation of the specific effectiveness of I-kappa-kinases or cyclic nucleotide phosphodiesterases (PDEs) which have the ability to cleave cGMP or cAMP. The preferred mode of action is dislocation, disruption of targeting or interference with redistribution of specific isoforms or splice variants of PDE4, PDE5, or I-kappa-kinases from their anchoring sites within cells, thereby modulating their specific effectiveness, not their enzymatic capacity. The chemical entities may be useful in preventing or treating in an animal, preferably a human, in need thereof an adverse condition which may be reduced or abolished by modulating the specific effectiveness of PDE4, PDE5, or I-kappa-kinases.
PCT/DK1999/000567 1998-10-15 1999-10-15 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases WO2000023091A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99948735A EP1146888A2 (en) 1998-10-15 1999-10-15 Specific therapeutic interventions obtained by interference with redistribution and/or targetting
JP2000576864A JP2003526608A (en) 1998-10-15 1999-10-15 Specific therapeutic intervention obtained by interference with redistribution and / or targeting
CA002346937A CA2346937A1 (en) 1998-10-15 1999-10-15 Specific therapeutic interventions obtained by interference with redistribution and/or targeting
AU61899/99A AU6189999A (en) 1998-10-15 1999-10-15 Specific therapeutic interventions obtained by interference with redistribution and/or targetting

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA199801323 1998-10-15
DKPA199801321 1998-10-15
DKPA199801322 1998-10-15
DKPA199801321 1998-10-15
DKPA199801322 1998-10-15
DKPA199801323 1998-10-15

Publications (2)

Publication Number Publication Date
WO2000023091A2 WO2000023091A2 (en) 2000-04-27
WO2000023091A3 true WO2000023091A3 (en) 2000-07-13

Family

ID=27221225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK1999/000567 WO2000023091A2 (en) 1998-10-15 1999-10-15 Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases

Country Status (5)

Country Link
EP (1) EP1146888A2 (en)
JP (1) JP2003526608A (en)
AU (1) AU6189999A (en)
CA (1) CA2346937A1 (en)
WO (1) WO2000023091A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851449B2 (en) 2013-07-03 2023-12-26 Takeda Pharmaceutical Company Limited Heterocyclic amide compounds having an RORvt inhibitory action

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19950647A1 (en) * 1999-10-21 2001-04-26 Merck Patent Gmbh Benzopyranoimidazolone and benzothiopyranoimidazolone derivatives as phosphodiesterase-VII inhibitors useful for treatment of e.g. asthma, psoriasis, osteoporosis, cachexia, sepsis, tumors and AIDS
US20030054531A1 (en) * 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
KR20040053210A (en) 2001-11-02 2004-06-23 화이자 프로덕츠 인크. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
JP2006500068A (en) * 2002-09-25 2006-01-05 デコード ジェネティクス イーエッチエフ． Human stroke susceptibility gene; therapy
BRPI0408500A (en) * 2003-03-17 2006-03-07 Pfizer Prod Inc Type 1 diabetes treatment with pde5 inhibitors
US8637528B2 (en) 2007-03-27 2014-01-28 Omeros Corporation Use of PDE7 inhibitors for the treatment of movement disorders
UA115057C2 (en) 2012-04-25 2017-09-11 Такеда Фармасьютікал Компані Лімітед Nitrogenated heterocyclic compound
EP2873669A4 (en) 2012-07-13 2015-11-25 Takeda Pharmaceutical Heterocyclic compound
WO2014142255A1 (en) 2013-03-14 2014-09-18 武田薬品工業株式会社 Heterocyclic compound
JP6427491B2 (en) 2013-07-03 2018-11-21 武田薬品工業株式会社 Heterocyclic compounds
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
MX2019014960A (en) * 2017-06-12 2020-08-06 Obsidian Therapeutics Inc Pde5 compositions and methods for immunotherapy.
WO2018237323A1 (en) * 2017-06-23 2018-12-27 The Board Of Trustees Of The Leland Stanford Junior University Pde5a destabilizing domains
CN114651003A (en) 2019-09-10 2022-06-21 黑曜石疗法公司 CA2-IL15 fusion protein for adjustable regulation

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001305A1 (en) * 1989-07-22 1991-02-07 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
WO1998008955A1 (en) * 1996-08-26 1998-03-05 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase [ikk] signalsome
WO1998037228A1 (en) * 1997-02-25 1998-08-27 The Regents Of The University Of California IλB KINASE, SUBUNITS THEREOF, AND METHODS OF USING SAME
WO1998045704A2 (en) * 1997-04-07 1998-10-15 Bioimage A/S A method for extracting quantitative information relating to an influence on a cellular response
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001305A1 (en) * 1989-07-22 1991-02-07 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
WO1998008955A1 (en) * 1996-08-26 1998-03-05 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase [ikk] signalsome
WO1998037228A1 (en) * 1997-02-25 1998-08-27 The Regents Of The University Of California IλB KINASE, SUBUNITS THEREOF, AND METHODS OF USING SAME
WO1998045704A2 (en) * 1997-04-07 1998-10-15 Bioimage A/S A method for extracting quantitative information relating to an influence on a cellular response
US5851812A (en) * 1997-07-01 1998-12-22 Tularik Inc. IKK-β proteins, nucleic acids and methods

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
XP002900999 *
XP002901000 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11851449B2 (en) 2013-07-03 2023-12-26 Takeda Pharmaceutical Company Limited Heterocyclic amide compounds having an RORvt inhibitory action

Also Published As

Publication number Publication date
WO2000023091A2 (en) 2000-04-27
AU6189999A (en) 2000-05-08
CA2346937A1 (en) 2000-04-27
EP1146888A2 (en) 2001-10-24
JP2003526608A (en) 2003-09-09

Similar Documents

Publication Publication Date Title
WO2000023091A3 (en) Specific therapeutic interventions obtained by interference with redistribution and/or targeting of cyclic nucleotide phosphodiesterases of i-kappa-b kinases
WO2002087419A3 (en) Biological pacemaker
HUP0104258A2 (en) Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitor
WO2003032912A8 (en) Treatment of cns disorders using cns target modulators
WO1998029105A3 (en) Method of treating prostatic diseases using delayed and/or sustained release vitamin d formulations
IL177228A0 (en) Use of a vector for the manufacture of a medicament for treating gaucher disease
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
DE60026538D1 (en) PHARMACEUTICAL PREPARATIONS THE CLAVULANIC ACID OR DERIVATIVES CONTAIN FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
DE69414114D1 (en) COLD STERILIZER WITH EXTENDED ACTIVITY
WO2002009713A3 (en) Selective pde 2 inhibitors, used as medicaments for improving cognition
DE50014190D1 (en) USE OF PHTHALAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
AU2821895A (en) Stable gel formulation for topical treatment of skin conditions
EP0919622A3 (en) Surface expression of enzyme in gene directed prodrug therapy
WO2004042033A3 (en) Circulating stem cells and uses related thereto
WO2003068148A3 (en) Treatment of sleep disorders using sleep target modulators
NZ505742A (en) Compositions containing aminobiguanides with antimicrobial activity used to treat contact lenses
FR2772622B1 (en) ACTIVE CONFIGURABLE IMPLANTABLE MEDICAL DEVICE, IN PARTICULAR CARDIAC STIMULATOR, DEFIBRILLATOR AND / OR CARDIOVERVER
PT855916E (en) PHARMACEUTICAL COMPOSITION CONTAINING AN ACTIVINE OR INHIBIT STIMULATOR
HUP0202744A2 (en) Oral controlled release formulations containing rivastigmine
WO1998050065A3 (en) The use of biologically active substances for influencing the extracellular area of sensory cells and method for controlling the administration of active substances and device used therein
WO2001089558A3 (en) Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
ATE297714T1 (en) EXTENDED RELEASE FORMULATIONS FOR IMPLANTATION
WO2004080530A3 (en) Specific method for implantable cardiac control
WO2002029099A1 (en) Method of screening physiologically active substance
AU2944100A (en) Gene therapeutics

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 576864

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2346937

Country of ref document: CA

Ref country code: CA

Ref document number: 2346937

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1999948735

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09806701

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1999948735

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1999948735

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999948735

Country of ref document: EP